London-based digital health company Medopad Ltd. has signed over 100 million pounds ($141 million) in commercial projects and partnerships with Chinese firms, the company said Thursday.
Among the 15 different partnerships and projects the company announced were a collaboration with China’s Tencent Holdings to use artificial intelligence to support doctors’ decision-making, as well as deals with China Resources, Ping An Good Doctor, Lenovo New Vision, GSK China, UMP Healthcare Holdings Ltd., and Johnson & Johnson’s Vision Care division in Shanghai and its Actelion China pharmaceutical company.
Medopad sells a mobile app that lets doctors remotely monitor and connect with patients, as well as provide analytics that help improve their care. The company is working with UBS Group AG to raise up to $30 million from private investors, Bloomberg reported in August.